De Novo NAFLD has been described in 20% of hepatic transplant recipients with no prior history of fatty liver disease, while de Novo NASH has been described in 10% of these patients 18. Dumortier et al.
En receptores de trasplante hepático sin historia previa de hígado graso se ha descrito NAFLD de novo en el 20% y NASH de novo en el 10% 18.